154 related articles for article (PubMed ID: 29137408)
1. Incidence and risk of regorafenib-induced hepatotoxicity.
Zhao B; Zhao H
Oncotarget; 2017 Oct; 8(48):84102-84111. PubMed ID: 29137408
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.
Zhao B; Zhao H
Oncotarget; 2017 Nov; 8(55):93813-93824. PubMed ID: 29212191
[TBL] [Abstract][Full Text] [Related]
3. Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Kapadia S; Hapani S; Choueiri TK; Wu S
Acta Oncol; 2013 Aug; 52(6):1202-12. PubMed ID: 23594201
[TBL] [Abstract][Full Text] [Related]
4. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.
Yin X; Yin Y; Shen C; Chen H; Wang J; Cai Z; Chen Z; Zhang B
Onco Targets Ther; 2018; 11():6405-6414. PubMed ID: 30323618
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.
Liu B; Yuan M; Sun Y; Cheng Z; Zhang Z; Hou S; Wang X; Liu J
Oncotarget; 2018 Feb; 9(10):9480-9488. PubMed ID: 29507704
[TBL] [Abstract][Full Text] [Related]
6. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
Schutz FA; Je Y; Choueiri TK
Crit Rev Oncol Hematol; 2011 Nov; 80(2):291-300. PubMed ID: 21339073
[TBL] [Abstract][Full Text] [Related]
7. Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
Zarrabi K; Wu S
Oncology; 2018; 94(5):259-273. PubMed ID: 29539626
[TBL] [Abstract][Full Text] [Related]
8. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
9. Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.
Iacovelli R; Palazzo A; Procopio G; Santoni M; Trenta P; De Benedetto A; Mezi S; Cortesi E
Br J Clin Pharmacol; 2014 Jun; 77(6):929-38. PubMed ID: 23981115
[TBL] [Abstract][Full Text] [Related]
10. Higher risk of hepatotoxicity associated with cabozantinib in cancer patients.
Wang Z; Jiang L; Lv X; Yin H; Wang Z; Li W; Liu Y
Crit Rev Oncol Hematol; 2024 Apr; 196():104298. PubMed ID: 38364886
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis.
Fu J; Li WZ; McGrath NA; Lai CW; Brar G; Xiang YQ; Xie C
Front Oncol; 2021; 11():650292. PubMed ID: 33968750
[TBL] [Abstract][Full Text] [Related]
12. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Opin Drug Saf; 2014 Aug; 13(8):999-1008. PubMed ID: 24930544
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Luo W; Wang Z; Tian P; Li W
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
[TBL] [Abstract][Full Text] [Related]
14. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
15. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials.
Ghatalia P; Je Y; Mouallem NE; Nguyen PL; Trinh QD; Sonpavde G; Choueiri TK
Crit Rev Oncol Hematol; 2015 Mar; 93(3):257-76. PubMed ID: 25523486
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials.
Cao M; Li F; Wang Y; Zhang J
Invest New Drugs; 2017 Dec; 35(6):834-838. PubMed ID: 28936569
[TBL] [Abstract][Full Text] [Related]
17. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis.
Teo YL; Ho HK; Chan A
Cancer Treat Rev; 2013 Apr; 39(2):199-206. PubMed ID: 23099278
[TBL] [Abstract][Full Text] [Related]
18. Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.
Fujiwara Y; Horita N; Harrington M; Namkoong H; Miyashita H; Galsky MD
Cancer Immunol Immunother; 2022 Dec; 71(12):2837-2848. PubMed ID: 35471602
[TBL] [Abstract][Full Text] [Related]
19. Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases.
Kumamoto K; Endo S; Isohata N; Nirei A; Nemoto D; Utano K; Saito T; Togashi K
Mol Clin Oncol; 2017 Jan; 6(1):63-66. PubMed ID: 28123730
[TBL] [Abstract][Full Text] [Related]
20. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Expert Opin Drug Saf; 2015 Oct; 14(10):1507-18. PubMed ID: 26394770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
